166 related articles for article (PubMed ID: 33673019)
1. Quality by Design Applied Development of Immediate-Release Rabeprazole Sodium Dry-Coated Tablet.
Lee SH; Kim JE
Pharmaceutics; 2021 Feb; 13(2):. PubMed ID: 33673019
[TBL] [Abstract][Full Text] [Related]
2. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
Chen C; Bujanover S; Kareht S; Rapoport AM
Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
[TBL] [Abstract][Full Text] [Related]
3. Development of a Fast Onset Proton Pump Inhibitor: Comparison of Fixed-Dose Combination of Rabeprazole and Sodium Bicarbonate (YPI-011) to the Conventional Enteric-Coated Rabeprazole.
Bae S; Kwon J; Lee MH; Yu KS; Lee S
Drug Des Devel Ther; 2023; 17():497-506. PubMed ID: 36814893
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic evaluation of differential drug release formulations of rabeprazole in dogs.
Patel H; Desai N; Patel P; Modi N; Soni K; Patel JR; Mistry GN; Patel JD; Chawla M; Srinivas NR
Drug Dev Ind Pharm; 2019 Sep; 45(9):1459-1467. PubMed ID: 31216902
[No Abstract] [Full Text] [Related]
5. Use of bicarbonate buffer systems for dissolution characterization of enteric-coated proton pump inhibitor tablets.
Shibata H; Yoshida H; Izutsu K; Goda Y
J Pharm Pharmacol; 2016 Apr; 68(4):467-74. PubMed ID: 27019275
[TBL] [Abstract][Full Text] [Related]
6. Design of fixed dose combination and physicochemical characterization of enteric-coated bilayer tablet with circadian rhythmic variations containing telmisartan and pravastatin sodium.
Luo D; Kim JH; Park C; Oh E; Park JB; Cui JH; Cao QR; Lee BJ
Int J Pharm; 2017 May; 523(1):343-356. PubMed ID: 28330645
[TBL] [Abstract][Full Text] [Related]
7. Design and evaluation of a dry coated drug delivery system with floating-pulsatile release.
Zou H; Jiang X; Kong L; Gao S
J Pharm Sci; 2008 Jan; 97(1):263-73. PubMed ID: 17803198
[TBL] [Abstract][Full Text] [Related]
8. Rabeprazole sodium delayed-release multiparticulates: Effect of enteric coating layers on product performance.
Tirpude RN; Puranik PK
J Adv Pharm Technol Res; 2011 Jul; 2(3):184-91. PubMed ID: 22171316
[TBL] [Abstract][Full Text] [Related]
9. Formulation and evaluation of sustained release matrix tablet of rabeprazole using wet granulation technique.
Khan R; Ashraf MS; Afzal M; Kazmi I; Jahangir MA; Singh R; Chandra R; Anwar F
J Pharm Bioallied Sci; 2014 Jul; 6(3):180-4. PubMed ID: 25035637
[TBL] [Abstract][Full Text] [Related]
10. Stereoselective pharmacokinetics of (R)-(+)- and (S)-(-)-rabeprazole in human using chiral LC-MS/MS after administration of rabeprazole sodium enteric-coated tablet.
Sun LN; Shen YW; Ying YW; Li D; Li TF; Zhang XH; Zhao P; Ding L; Wang YQ
Chirality; 2018 Dec; 30(12):1277-1286. PubMed ID: 30321480
[TBL] [Abstract][Full Text] [Related]
11. Design of nateglinide controlled release tablet containing erosion matrix tablet and multiple administration study in normal beagle dogs.
Makino C; Sakai H; Okano A; Yabuki A
Chem Pharm Bull (Tokyo); 2009 Sep; 57(9):907-13. PubMed ID: 19721250
[TBL] [Abstract][Full Text] [Related]
12. Influence of excipients, drugs, and osmotic agent in the inner core on the time-controlled disintegration of compression-coated ethylcellulose tablets.
Lin SY; Lin KH; Li MJ
J Pharm Sci; 2002 Sep; 91(9):2040-6. PubMed ID: 12210050
[TBL] [Abstract][Full Text] [Related]
13. Delayed release film coating applications on oral solid dosage forms of proton pump inhibitors: case studies.
Missaghi S; Young C; Fegely K; Rajabi-Siahboomi AR
Drug Dev Ind Pharm; 2010 Feb; 36(2):180-9. PubMed ID: 20070183
[TBL] [Abstract][Full Text] [Related]
14. Development of Clinically Optimized Sitagliptin and Dapagliflozin Complex Tablets: Pre-Formulation, Formulation, and Human Bioequivalence Studies.
Kang SJ; Kim JE
Pharmaceutics; 2023 Apr; 15(4):. PubMed ID: 37111730
[TBL] [Abstract][Full Text] [Related]
15. Compression forces and amount of outer coating layer affecting the time-controlled disintegration of the compression-coated tablets prepared by direct compression with micronized ethylcellulose.
Lin KH; Lin SY; Li MJ
J Pharm Sci; 2001 Dec; 90(12):2005-9. PubMed ID: 11745759
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of the controlled-release nisoldipine coat-core tablet formulation.
Heinig R; Ahr G; Hayauchi Y; Kuhlmann J
Int J Clin Pharmacol Ther; 1997 Aug; 35(8):341-51. PubMed ID: 9266290
[TBL] [Abstract][Full Text] [Related]
17. Review article: immediate-release proton-pump inhibitor therapy--potential advantages.
Howden CW
Aliment Pharmacol Ther; 2005 Dec; 22 Suppl 3():25-30. PubMed ID: 16303034
[TBL] [Abstract][Full Text] [Related]
18. Exploring Differences in Pharmacometrics of Rabeprazole between Genders via Population Pharmacokinetic-Pharmacodynamic Modeling.
Jeong SH; Jang JH; Lee YB
Biomedicines; 2023 Nov; 11(11):. PubMed ID: 38002021
[TBL] [Abstract][Full Text] [Related]
19. Formulation design of double-layer in the outer shell of dry-coated tablet to modulate lag time and time-controlled dissolution function: studies on micronized ethylcellulose for dosage form design (VII).
Lin SY; Lin KH; Li MJ
AAPS J; 2004 Jul; 6(3):e17. PubMed ID: 15760102
[TBL] [Abstract][Full Text] [Related]
20. Understanding the in vivo performance of enteric coated tablets using an in vitro-in silico-in vivo approach: case example diclofenac.
Kambayashi A; Blume H; Dressman J
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1337-47. PubMed ID: 24056057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
